Market Signal Briefing

DOGE shows strong support at $0.08 and resistance at $0.20, entering a third accumulation phase that could drive price toward $0.80.

Newton Gitonga2 min read

29 November 2025, 02:49 PM

Dogecoin briefly spiked above $0.155 before losing momentum and sliding back toward the $0.150 zone. Since then, the price has moved mostly sideways with mild volatility, showing weak buying pressure.

As of this writing, Dogecoin is exchanging hands at around $0.1494 with a 24-hour loss of 0.99%.

DOGE price chart, Source: CoinMarketCap

DOGE Price Stability Hinges on the $0.08 Support RangeAccording to recent data by analyst Ali Martinez, the Dogecoin Cost Basis Distribution Heatmap clearly shows that a substantial portion of holders accumulated their DOGE positions around the $0.08 support zone, creating a strong foundation for price stability. This dense cluster of buying activity represents a psychologically and technically significant level. 

Investors who bought here are deeply positioned and typically react by adding more to their holdings or refusing to sell when the price retests this region. This behavior naturally reinforces the support, making $0.08 a critical defensive line where buyer conviction tends to outweigh selling pressure, limiting the likelihood of a deeper breakdown.

Source: X

On the opposite side, Martinez highlights the $0.20–$0.21 range as a major resistance barrier defined by heavy cost-basis concentration above the current price. The heatmap shows that many DOGE holders entered the market at these higher levels, and as the price approaches this area, they may be inclined to sell, break even, or reduce exposure, creating strong overhead supply. Martinez often explains that such upper accumulation blocks act as walls that cap upward momentum until a decisive breakout occurs with strong volume. 

DOGE Poised for Major Bullish Breakout Amid Third Accumulation PhaseAnalyst Bitcoinsensus highlights a clear cyclical pattern in Dogecoin’s price action, observable in the chart. The cryptocurrency has repeatedly moved through phases of accumulation followed by upward price waves. The chart identifies three main accumulation zones, each leading to progressively larger bullish moves. The first accumulation saw a 190% surge, while the second led to a remarkable 480% rally. These periods of sideways trading indicate strong investor interest and the building of buying pressure, which typically precedes substantial price increases.

Source: X

Currently, Dogecoin appears to be in the third accumulation phase. If this historical pattern continues, this phase could lead to an even larger bullish wave, potentially pushing DOGE toward new all-time highs around $0.80. The RSI indicator also suggests oversold conditions, supporting the likelihood of a strong upward movement once the accumulation concludes. The chart and prior cycles underscore a predictable pattern: extended accumulation periods are followed by progressively larger price surges, signaling a promising bullish setup for investors.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Newton Gitonga

Newton Gitonga covers cryptocurrencies, blockchain, and digital finance. He specializes in breaking down complex trends with clear, data-driven reporting. His work focuses on market analysis, technical insights, and the evolving role of altcoins in shaping global markets.

Read more about

Dogecoin (DOGE) News

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

A leading finance expert believes that the current growth stage of the Bitcoin price mirrors Google’s expansion in 2017, suggesting that the network is yet to reach its true potential. The expert’s comparison positions Bitcoin as a maturing digital system that has established core utility, with a larger phase of value capture still ahead. His remarks about BTC come at a time when its price is navigating sharp downside risks and heightened market volatility

How The Bitcoin Price Compares To Google In 2017
Raoul Pal, the founder and Chief Executive Officer (CEO) of Real Vision, has highlighted a compelling connection between Bitcoin’s current price growth and Google’s early years. In an X post this week, Pal argued that digital assets clearly follow a network-driven growth model, comparing the sector to major technology giants that expanded rapidly as their user base increased. 

The Real Vision founder emphasized that crypto behaves like a Metcalfe’s Law network, similar to Google, Amazon, Meta, and Tesla, where value scales with the number of participants rather than traditional financial metrics. He stated that attempting to value cryptocurrencies using cash flow models overlooks the essence of what makes a network valuable. 

Source: Chart from Raoul Pal on X
In his view, the structure of blockchain ecosystems means that their worth is tied to usage, adoption, and the network effects generated by millions of users. This unique framework underpins Pal’s belief that Bitcoin’s price growth today is a reflection of Google’s position in 2017. The financial expert supported his argument with a GOOGL US equity chart, showing its multi-year growth curve on a logarithmic scale. During 2017, Google was already dominant in areas like search, yet many of its long-term value drivers, such as cloud and Artificial Intelligence (AI), were still developing. 

While the Bitcoin network is secure, widely adopted, and increasingly integrated into the global financial system, Pal’s view suggests that the cryptocurrency’s long-term development and true potential are still far from realized. He added that Ethereum may be even earlier in its growth curve, suggesting the second-largest cryptocurrency could follow a longer trajectory as its technology and applications evolve.  

The True Value of Crypto Networks
Pal’s remarks on X, which compares Bitcoin to Google, were made in response to statements from Santiago Roel Santos, the founder and CEO of Inversion, a technology-first investment company. Santos initially argued that network effects in crypto have been overstated and are often misused to justify valuations resembling those of social networking companies. 

Santos suggested that many cryptocurrencies have not demonstrated meaningful value capture and therefore resemble open source software systems like Linux rather than platforms such as Facebook, which benefit directly from rising user numbers. Pal challenged this view by insisting that crypto networks exhibit real and measurable network effects. His entire argument is built on the idea that user activity and transaction volume support the growing value of digital networks like Bitcoin.  

BTC trading at $90,536 on the 1D chart | Source: BTCUSDT on Tradingview.com
Featured image from Pngtree, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Scott Matherson is a leading crypto writer at Bitcoinist, who possesses a sharp analytical mind and a deep understanding of the digital currency landscape. Scott has earned a reputation for delivering thought-provoking and well-researched articles that resonate with both newcomers and seasoned crypto enthusiasts.
Outside of his writing, Scott is passionate about promoting crypto literacy and often works to educate the public on the potential of blockchain.

Blockchain analytics platform XWIN Research Japan shares that Bitcoin’s NPRL has returned to a neutral zone following a period of significant volatility. This development represents one of many positives following Bitcoin’s modest price gain over the last week.

NPRL Shows Balanced Market, New Trend Forms On Horizon
The Net Realized Profit and Loss (NRPL) is an on-chain metric that measures the total profit or loss that Bitcoin holders realize when they sell their coins at a given price. A positive NRPL suggests more BTC are being sold at a profit rather than at a loss, i.e., market participants are realizing gains, while a negative NRPL means more BTC are being sold at a loss than at a profit.

According to analysts at XWIN Research Japan, Bitcoin’s NPRL registered significant positive and negative deviations between November 22 and 24. However, the metric has stabilized in its neutral zone since November 25, as Bitcoin achieved a sustained market recovery. At near-zero NRPL, realized gains and losses are roughly balanced, suggesting market indecision or consolidation. This period usually comes after periods of market capitulation, marking a transition from a volatile phase to a calmer market environment.

Source: CryptoQuant
As earlier stated, the stabilization of NRPL aligns with Bitcoin’s price action, which has recently risen to steady around the $90,000 range. The lack of significant upward or downward pressure suggests that the market is digesting recent volatility and building a foundation for future movements. Analysts at XWIN state similar NRPL neutralization from the past phases has preceded the emergence of new trends, indicating BTC price may be consolidating for a new direction.

What Next For Bitcoin? 
Looking ahead, XWIN Research Japan states the critical factor will be whether NRPL maintains its position above the zero line or slips back into negative territory. A sustained positive NRPL would indicate improving demand and healthier inflows, potentially supporting a stronger recovery. Conversely, a return to negative NRPL could signal renewed weakness and the potential for another round of selling pressure.

In summary, the recent pattern, from deep negative swings to positive spikes, followed by convergence near zero, demonstrates that the market’s internal structure has largely reset and has completed its clearing phase for a new price trend to emerge.

At the time of writing, Bitcoin trades at $90,485 after a minor 0.65% loss in the last 24 hours. Meanwhile, its daily trading volume is up by 14.06% and valued at $57.04 billion.

BTC trading at $90,459 on the daily chart | Source: BTCUSDT chart on Tradingview.com
Featured image from Pngtree, chart from Tradingview

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Molina To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Molina between February 5, 2025 and July 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) material, adverse facts concerning the Company’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 7, 2025, before the market opened, Molina issued a press release announcing financial results for the second quarter of 2025 and slashing full year 2025 adjusted earnings per share guidance. The press release revealed the Company’s second quarter 2025 adjusted earnings of approximately $5.50 per share, which was “below its prior expectations” due to “medical cost pressures in all three lines of business.” The Company announced it “expects these medical cost pressures to continue into the second half of the year” and cut guidance for expected adjusted earnings per share 10.2% at the midpoint, from “at least $24.50 per share” to a “range of $21.50 to $22.50 per share.” The press release revealed Molina was experiencing a “short-term earnings pressure” from a “dislocation between premium rates and medical cost trend which has recently accelerated.”

On this news, Molina’s stock price fell $6.97, or 2.9%, to close at $232.61 per share on July 7, 2025, on unusually heavy trading volume.

Then, on July 23, 2025, after the market closed, Molina issued a press release reporting its financial results for the second quarter ended June 30, 2025 and further slashing the Company’s full-year 2025 earnings guidance. The press release revealed, in part, that the Company’s “GAAP net income was $4.75 per diluted share for the second quarter of 2025, a decrease of 8% year over year;” and it “now expects its full year 2025 adjusted earnings to be no less than $19.00 per diluted share.” This represented another 13.6% cut to guidance of earnings per share at the midpoint, from the cut to guidance announced less than two weeks earlier. The Company also cut its guidance for its full year 2025 GAAP net income 27% to $912 million. The Company attributed its results a full year outlook to a “challenging medical cost trend environment,” including mere “utilization of behavioral health, pharmacy, and inpatient and outpatient services.” The Company alleged its guidance cut also reflected “new information gained in the quarterly closing process.”

On this news, Molina’s stock price fell $32.03, or 16.84%, to close at $158.22 per share on July 24, 2025, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Molina’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Molina Healthcare, Inc. class action, go to www.faruqilaw.com/MOH or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c4b666-65e2-42bc-b437-227a7c8e271d

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Stride To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Stride between October 22, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN) and reminds investors of the January 12, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose information regarding the Company’s products and services to public and private schools, school districts, and charter boards. Throughout the Class Period, Stride represented to investors that “[t]hese products and services, spanning curriculum, systems, instruction, and support services are designed to help learners of all ages reach their full potential through inspired teaching and personalized learning.” Unbeknownst to investors, Stride was inflating enrollment numbers, cutting staff costs beyond required statutory limits, ignoring compliance requirements, and losing existing and potential enrollments.

On September 14, 2025, Simply Wall St. published a report stating that the Gallup-McKinley County Schools Board of Education had filed a complaint against Stride, alleging fraud, deceptive trade practices, systemic violations of law, and intentional and tortious misconduct, including inflating enrollment numbers by retaining “ghost students” on rolls to secure state funding per student and ignoring compliance requirements, including background checks and licensure laws for its employees.

On this news, Stride’s stock price fell $18.60, or 11.7%, to close at $139.76 per share on September 15, 2025, thereby injuring investors.

Then, on October 28, 2025, Stride released its first quarter fiscal 2026 financial results, revealing the Company had purposely “limit[ed] enrollment growth while we improve our execution.” The Company also revealed it had experienced “system implantation issues” resulting in “higher withdrawal rates and lower conversion rate.” The Company stated that “these factors resulted in approximately 10,000 to 15,000 fewer enrollments” and “these challenges will likely restrict [its] in-year enrollment growth.”

On this news, Stride’s stock price fell as much as 51% during intraday trading on October 29, 2025, thereby injuring investors further.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Stride’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Stride class action, go to www.faruqilaw.com/LRN or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c4b666-65e2-42bc-b437-227a7c8e271d

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inspire Medical To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Inspire Medical between August 6, 2024 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inspire Medical Systems, Inc. (“Inspire Medical” or the “Company”) (NYSE: INSP) and reminds investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose key facts about Inspire V, including the actual market demand for the device and whether the company had taken the steps necessary to successfully launch it. Defendants issued a series of materially false and misleading statements that led investors to believe demand for Inspire V was strong and that Company had taken the necessary steps for a successful launch.

On August 4, 2025, Inspire Medical Systems announced significant setbacks in the launch of its new Inspire V device. The company revealed that the rollout was taking much longer than expected because many treatment centers had not yet completed the required training, contracting, and onboarding needed to begin using the product. Inspire also disclosed billing and reimbursement challenges, explaining that although Medicare had approved a CPT code for Inspire V, the necessary software updates for claims processing did not go into effect until July 1. As a result, implanting centers could not bill for procedures before that date and instead continued using the older Inspire IV system.

In addition to these logistical and reimbursement problems, Inspire reported that the Inspire V launch was suffering from weak demand and excess inventory. These issues forced the company to sharply cut its 2025 earnings guidance by more than 80%. Following these revelations, Inspire’s stock price fell more than 32% in a single day—from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025—wiping out approximately $1.2 billion in market capitalization.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Inspire Medical’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Inspire Medical class action, go to www.faruqilaw.com/INSP or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c4b666-65e2-42bc-b437-227a7c8e271d

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. (“Skye” or the “Company”) (Nasdaq: SKYE) and reminds investors of the January 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

On October 6, 2025, Skye issued a press release "announcing the topline data from its 26-week Phase 2a CBeyond™ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody." The press release disclosed that the "the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo" and that "preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy."

On this news, Skye's stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Skye’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Skye Bioscience class action, go to www.faruqilaw.com/SKYE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c4b666-65e2-42bc-b437-227a7c8e271d

Given the inflationary forces at play in recent decades, achieving a seven-digit portfolio isn't what it once used to be.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Synopsys To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Synopsys between December 4, 2024 and September 9, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Synopsys, Inc. (“Synopsys” or the “Company”) (NASDAQ: SNPS) and reminds investors of the December 30, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the extent to which the Company’s increased focus on artificial intelligence customers, which require additional customization, was deteriorating the economics of its Design IP business; (2) that, as a result, “certain road map and resource decisions” were unlikely to “yield their intended results;” (3) that the foregoing had a material negative impact on financial results; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On September 9, 2025, after market hours, Synopsys released its third quarter 2025 financial results, revealing the Company’s “IP business underperformed expectations.” The Company reported quarterly revenue of $1.740 billion, missing its prior guidance of between $1.755 billion and $1.785 billion, and reported net income of $242.5 million, a 43% year-over-year decline from $425.9 million reported for third quarter 2024. Moreover, the Company reported its Design IP segment accounted for approximately 25% of revenue and came in at $426.6 million, a 7.7% decline year-over-year. Finally, management provided guidance which implied that Design IP revenues will decline by at least 5% on a full-year basis in fiscal 2025.

On this news, Synopsys’s stock price fell $216.59, or 35.8%, to close at $387.78 per share on September 10, 2025, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Synopsys’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Synopsys class action, go to www.faruqilaw.com/SNPS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c4b666-65e2-42bc-b437-227a7c8e271d

Analyst’s Disclosure:I/we have a beneficial long position in the shares of NBIS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Avantor To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Avantor between March 5, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR) and reminds investors of the December 29, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Avantor’s competitive positioning was weaker than Defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, Defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

During the Class Period, Defendants misled investors by falsely touting the Company’s competitive positioning and downplaying the effects of increased competition. For example, during an earnings call on July 26, 2024, in response to an analyst’s question about whether Avantor was losing share to a competitor, Defendant Michael Stubblefield, then the Company’s President and Chief Executive Officer, assured investors that Avantor’s “lab business stacks up well against every number that certainly that we’ve seen,” that “we continue to enhance our position,” and that “we’re really confident in our value proposition and our competitive position.” Likewise, Defendants repeatedly pointed to Avantor’s purported competitive advantages, such as its digital capabilities, as evidence that the Company would continue to enjoy strong competitive positioning.

Investors began to learn the truth about the effects of increased competition on Avantor’s business on April 25, 2025, when the Company reported disappointing first quarter 2025 financial results, cut its guidance for 2025, and announced that Defendant Stubblefield would be stepping down from his roles as President and Chief Executive Officer. Defendants attributed Avantor’s weak performance and outlook to “the impact of increased competitive intensity.”

On this news, the price of Avantor common stock declined $2.57 per share, or more than 16.5%, from a close of $15.50 per share on April 24, 2025, to close at $12.93 per share on April 25, 2025

Then, on August 1, 2025, the Company reported disappointing second quarter 2025 financial results, including a year-over-year decrease in net sales, and further reduced the Company’s 2025 guidance—now projecting organic revenue growth of -2% to 0%. Defendants again attributed Avantor’s poor results and outlook to “increased competitive intensity,” and further admitted that the Company did not expect the competitive environment to materially improve in the remainder of 2025 and weak performance would therefore likely persist.

In response to this news, the price of Avantor common stock declined $2.08 per share, or more than 15%, from a close of $13.44 per share on July 31, 2025, to close at $11.36 per share on August 1, 2025.

Then, on October 29, 2025, the Company reported weak third quarter 2025 financial results, including -5% organic revenue growth (below the guidance Defendants had provided in August), and a net loss of $712 million, which Defendants primarily attributed to a non-cash goodwill impairment charge of $785 million. Defendants revealed that the impairment charge was necessary due in part to “competitive pressures” that had “meaningfully impacted” the Company’s margins, and further admitted that the Company had lost several large accounts

On this news, the price of Avantor common stock declined $3.50 per share, or more than 23%, from a close of $15.08 per share on October 28, 2025, to close at $11.58 per share on October 29, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Avantor’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Avantor class action, go to www.faruqilaw.com/AVTR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c4b666-65e2-42bc-b437-227a7c8e271d

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In WPP To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in WPP between February 27, 2025 and July 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against WPP plc (“WPP” or the “Company”) (NYSE: WPP) and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material information concerning WPP’s expected revenue for the fiscal year 2025. Defendants’ statements included, among other things, confidence in the Company’s continued efforts to revitalize and simplify its media division to obtain new wins and retain clientele, repeated claims that the “ramp-up of new wins” and ongoing sales to existing clients would offset lost clientele, and a continued emphasis on the Company’s self-proclaimed “cautious” guidance that purportedly accounted for “broad macro uncertainty.” Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of WPP’s media arm; notably, that it was not truly equipped to handle the ongoing macroeconomic challenges while competing effectively and had instead begun to lose significant market share to its competitors. Such statements absent these material facts caused Plaintiff and other shareholders to purchase WPP’s securities at artificially inflated prices.

On July 9, 2025, WPP published a trading update for the first half of 2025, alerting investors that the company had allegedly “seen a deterioration in performance as Q2 has progressed.” The Company attributed its misfortune to both “continued macro uncertainty weighing on client spend and weaker net new business than originally anticipated,” at least in part due to “some distraction to the business” as a result of the continued restructuring of WPP Media a.k.a. GroupM.

Investors and analysts reacted immediately to WPP’s revelation. The price of WPP’s common stock declined dramatically. From a closing market price of $35.82 per share on July 8, 2025, WPP’s stock price fell to $29.34 per share on July 9, 2025, a decline of about 18.1% in the span of just a single day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding WPP’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the WPP class action, go to www.faruqilaw.com/WPP or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c4b666-65e2-42bc-b437-227a7c8e271d

Analyst’s Disclosure:I/we have a beneficial long position in the shares of BBY, AMZN, MSFT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Gold prices have undeniably taken a breather. After a historic run that saw the precious metal shatter record after record, surging past $4,500 per ounce in mid-October, the market has entered a distinct consolidation phase.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In James Hardie To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in James Hardie between May 20, 2025 and August 18, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against James Hardie Industries plc (“James Hardie” or the “Company”) (NYSE: JHX) and reminds investors of the December 23, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that James Hardie Industries plc misled investors about the strength of its key North America Fiber Cement segment between May 20 and August 18, 2025. Despite knowing by April and early May that distributors were destocking inventory, the company falsely claimed demand remained strong and that stock levels were “normal.”

On August 19, 2025, James Hardie issued a press release announcing financial results for its first quarter ended June 30, 2025. Among other items, James Hardie reported a 29% decline in first-quarter profit and projected lower-than-expected fiscal 2026 earnings, citing high borrowing costs.

On this news, James Hardie's American Depositary Receipt ("ADR") price fell $9.79 per ADR, or 34.44%, to close at $18.64 per ADR on August 20, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding James Hardie’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the James Hardie class action, go to www.faruqilaw.com/JHX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c4b666-65e2-42bc-b437-227a7c8e271d

HomeIndustriesAutomobilesCEO Elon Musk once described the Cybertruck as Tesla’s ‘best ever’ product. But demand for the controversial pickup truck has dried up.Published: Nov. 29, 2025 at 9:00 a.m. ET

This weekend marks two years since Tesla’s Cybertruck first went out for delivery. In that span, the bold pickup truck has proven a commercial letdown, especially relative to CEO Elon Musk’s expectations.

“Demand is so far off the hook, you can’t even see the hook,” Musk boasted in July 2023. More than 1 million people reserved their spot in line for one of the trucks, Musk said on an earnings call a few months later.

Partner CenterMost Popular

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

This mining company is poised to become the U.S.'s go-to supplier for rare earth magnets.

What do smartphones, laptops, washing machines, electric vehicles, televisions, power tools, and electric toothbrushes have in common? None of them would be possible without a tiny piece of hardware that most people have never seen: a high-performance magnet made from rare earth metals.

For years, the U.S. has been happy letting China handle the complex task of mining and processing the elements that go into those magnets. But that arrangement is starting to break down.

Trade tensions between the U.S. and China have led the former to invest substantially in certain mining companies that can help it shore up a domestic supply of metals. One of those is MP Materials (MP +2.99%), and it may be the company best positioned to fill that gap.

MP controls America's high-performance magnet supply
MP operates the Mountain Pass mine in California, one of the few rare earth mines of scale in the U.S. In addition to this, it runs the Independent magnet facility in Fort Worth, Texas, where it plans to integrate mining and magnet production into a single domestic chain.

Winding haul roads at the open pit mine at Mountain Pass. Image source: MP Materials.

Two partners have helped anchor MP's current dominance in the domestic rare earth market.

One is the Pentagon. In July, it agreed to invest about $400 million in MP through preferred stock, becoming in effect its largest shareholder. It also committed to buying all the magnets produced as its new magnet plant (10X Facility) for 10 years, while also agreeing to a generous price floor for rare earths neodymium and praseodymium.

Today's Change

(

2.99

%) $

1.80

Current Price

$

61.95

Days later, Apple (AAPL +0.46%) announced a separate $500 partnership. According to the deal, MP will supply American-made magnets from its Forth Worth plant starting in 2027, while Apple will prepay $200 million.

Near term, MP looks very much like a young company trying to expand. Third-quarter earnings showed a loss and zero revenue from concentrate sales after it stopped shipments to China under the new Pentagon agreements.

Still, for investors who think the U.S. is serious about shoring up critical minerals, MP is one way to play that policy bet directly.

Steven Porrello has positions in MP Materials. The Motley Fool has positions in and recommends Apple. The Motley Fool recommends MP Materials. The Motley Fool has a disclosure policy.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased aTyr Pharma common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

These funds have low fees and solid diversification, which can make them great investments to buy and hold.

The stock market has been hot in the past few years due to the robust demand growth in artificial intelligence (AI). From chatbots to agentic AI, there's been a flurry of new products and services that has made investors bullish on companies involved with new technologies.

The problem is that in the process, valuations for many stocks have ballooned to seemingly unsustainable levels. Many investors are unsure whether this is the start of a huge revolution, or if it's really just the latest bubble in tech. After all, many AI investments aren't paying off for companies, and a pullback in spending could be inevitable.

As a result, picking individual stocks is becoming increasingly challenging. If you're worried about a bubble and don't know what to invest in, there are some exchange-traded funds (ETFs) that could be good options to hang on to for the long haul.

Although they aren't entirely risk-free investments, the Vanguard Dividend Appreciation Index Fund ETF (VIG +0.48%) and Vanguard Growth Index Fund ETF (VUG +0.50%) are solid funds with low fees that pay dividends, and which can diversify your portfolio. Here's a closer look at why these ETFs can make for great investments today.

Image source: Getty Images.

Vanguard Dividend Appreciation Index Fund ETF
The Vanguard Dividend Appreciation Index Fund has a low expense ratio of 0.05%, making it a suitable option for long-term investors as fees are minimal in this fund. On a $10,000 investment, you're paying just $5 in fees per year. Meanwhile, you're getting an above-average yield of 1.6% in the process, which is higher than the S&P 500 average of 1.2%.

There are over 330 holdings in this ETF, with the focus being on stocks with track records for growing their dividend payments on an annual basis. For investors, those are solid stocks to invest in, because in order for them to grow their payouts, their financials need to be strong enough to support the dividend growth. While it isn't always the case, that can mean a safer mix of stocks.

The three largest holdings in the ETF are tech stocks: Broadcom, Microsoft, and Apple. Their strong financials enable them to grow their dividends consistently. While none of these stocks yield even 1%, over time, these might become among the best dividend stocks to own, simply because of their robust financials and sheer growth.

Today's Change

(

0.48

%) $

1.07

Current Price

$

222.67

However, tech stocks account for 29% of the fund's overall portfolio. There's some good diversification here, with financials representing 22% of the portfolio, followed by healthcare at 16%, and industrials at 11%. This year, the ETF has risen by 11%, as it continues to be an excellent investment.

Vanguard Growth Index Fund ETF
Another top Vanguard fund to consider for long-term safety is the Vanguard Growth Index Fund. It has an even smaller expense ratio of 0.04%. It isn't as much of a dividend play, as it yields 0.4%, but the dividend income can nonetheless more than offset the ETF's fees.

This fund gives investors exposure to the largest growth stocks in the U.S. It contains 160 holdings, and the overwhelming majority of them (more than 63%) are in the tech sector. There's much more exposure to tech with this fund. But 18% of its stocks are in the consumer discretionary sector, and another 8% are in industrials. This is still a relatively safe way to invest in the long haul, given the mix of top growth stocks you'll get exposure to, from multiple sectors.

Chipmaker Nvidia is the ETF's top holding, followed by Apple and Microsoft. You'll get the biggest names in tech in this fund. You'll also get top companies from other sectors, including Eli Lilly, a leading drugmaker which was recently the first healthcare stock to hit a $1 trillion valuation.

Today's Change

(

0.50

%) $

2.46

Current Price

$

490.84

This year, this Vanguard fund has climbed 16% in value as it has outperformed the S&P 500, which is up around 14%. The fund may suffer a decline if there is a correction or crash in the markets, but with a collection of top growth stocks in its portfolio, it's likely to recover in the long run. This can be another solid investment to put money into for the long term.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Spotify.

Getty Images

Up for a challenge? Test your knowledge on the biggest events in the investing world over the past week. Take the latest Seeking Alpha News Quiz and see how you stack up against the competition.

For Wall Street, the holiday-shortened Thanksgiving week was all about recovery.

After slumping to a monthly low closing level on November 20, at which point the benchmark S&P 500 index (SP500) was -4.4% for the month, the gauge posted a five-day win streak, which culminated on Black Friday with the S&P turning positive for the month. That swing from red to green was the largest ever for the month of November.

The mood among traders has swiftly improved, chiefly due to economic data that has supported an interest rate cut in December. Historical patterns of trading have also played a part, as markets generally tend to bottom on November 20 before the year-end Santa rally.

One of the most notable events this week was when investors returned from the Thanksgiving holiday on Black Friday to find trading across futures markets halted for several hours. The issue arose after CME Group (CME), the world's largest exchange operator, suffered an outage due to a cooling issue at some of its data centers. Trading was eventually restored, and the truncated Black Friday regular session saw no problems.

For the week, the S&P (SP500) surged +3.7%, while the blue-chip Dow (DJI) gained +3.2%. The tech-heavy Nasdaq Composite (COMP:IND) soared +4.9%. Read a preview of next week's major events in Seeking Alpha's Catalyst Watch.

Seeking Alpha's Calls Of The Week

Weekly Movement

U.S. Indices
Dow +3.2% to 47,716. S&P 500 +3.7% to 6,849. Nasdaq +4.9% to 23,366. Russell 2000 +5.5% to 2,500. CBOE Volatility Index -30.2% to 16.35. S&P 500 Sectors
Consumer Staples +1.7%. Utilities +2.9%. Financials +3.2%. Telecom +5.9%. Healthcare +1.9%. Industrials +2.7%. Information Technology +4.3%. Materials +3.3%. Energy +1%. Consumer Discretionary +5.3%. Real Estate +1.8%.

World Indices
London +1.9% to 9,721. France +1.8% to 8,123. Germany +3.2% to 23,837. Japan +3.4% to 50,254. China +1.4% to 3,889. Hong Kong +2.5% to 25,859. India +0.6% to 85,707.

Commodities and Bonds
Crude Oil WTI +0.8% to $58.55/bbl. Gold +3.7% to $4,269.8/oz. Natural Gas +5.9% to 4.85. Ten-Year Bond Yield -0.2 bps to 4.019.

Forex and Cryptos
EUR/USD +0.72%. USD/JPY -0.13%. GBP/USD +1.07%. Bitcoin +7.1%. Litecoin +4.2%. Ethereum +9.8%. XRP +12.2%.

Top S&P 500 Gainers
Robinhood Markets (HOOD) +21%. Intel (INTC) +21%. Builders FirstSource (BLDR) +18%. Analog Devices (ADI) +18%. Micron Technology (MU) +17%.

Top S&P 500 Losers
Copart (CPRT) -5%. Oracle (ORCL) -4%. Deere & Company (DE) -2%. Lockheed Martin (LMT) -2%. Texas Pacific Land (TPL) -2%.

Where will the markets be headed next week? Current trends and ideas? Add your thoughts to the comments section.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of DBX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ARE:CA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The author is not an investment advisor and offers no advice here. He shares his own analysis solely for the interest of readers.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.